These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 37804962)
21. Potential Repurposing of Drugs with Anti-SARS-CoV-2 Activity in Preclinical Trials: A Systematic Review. Rocha YM; de Moura GA; de Oliveira JR; de Figueiredo Nicolete LD; Nicolete R Curr Med Chem; 2021; 28(22):4577-4585. PubMed ID: 33019921 [TBL] [Abstract][Full Text] [Related]
22. Identifying SARS-CoV-2 Drugs Binding to the Spike Fatty Acid Binding Pocket Using In Silico Docking and Molecular Dynamics. Piplani S; Singh P; Petrovsky N; Winkler DA Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835602 [TBL] [Abstract][Full Text] [Related]
23. Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV. Aherfi S; Pradines B; Devaux C; Honore S; Colson P; Scola B; Raoult D Future Microbiol; 2021 Nov; 16():1341-1370. PubMed ID: 34755538 [TBL] [Abstract][Full Text] [Related]
24. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19. Blaess M; Kaiser L; Sommerfeld O; Csuk R; Deigner HP Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670304 [TBL] [Abstract][Full Text] [Related]
25. Repurposing novel therapeutic candidate drugs for coronavirus disease-19 based on protein-protein interaction network analysis. Adhami M; Sadeghi B; Rezapour A; Haghdoost AA; MotieGhader H BMC Biotechnol; 2021 Mar; 21(1):22. PubMed ID: 33711981 [TBL] [Abstract][Full Text] [Related]
26. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy. Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D Cells; 2021 Dec; 11(1):. PubMed ID: 35011614 [TBL] [Abstract][Full Text] [Related]
28. Discovery of Potential Therapeutic Drugs for COVID-19 Through Logistic Matrix Factorization With Kernel Diffusion. Tian X; Shen L; Gao P; Huang L; Liu G; Zhou L; Peng L Front Microbiol; 2022; 13():740382. PubMed ID: 35295301 [TBL] [Abstract][Full Text] [Related]
29. Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapy. Boytz R; Słabicki M; Ramaswamy S; Patten JJ; Zou C; Meng C; Hurst BL; Wang J; Nowak RP; Yang PL; Sattler M; Stone RM; Griffin JD; Gray NS; Gummuluru S; Davey RA; Weisberg E J Med Virol; 2023 Jan; 95(1):e28157. PubMed ID: 36117402 [TBL] [Abstract][Full Text] [Related]
30. Lung disease network reveals impact of comorbidity on SARS-CoV-2 infection and opportunities of drug repurposing. Das AB BMC Med Genomics; 2021 Sep; 14(1):226. PubMed ID: 34535131 [TBL] [Abstract][Full Text] [Related]
31. A transferable deep learning approach to fast screen potential antiviral drugs against SARS-CoV-2. Wang S; Sun Q; Xu Y; Pei J; Lai L Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34081143 [TBL] [Abstract][Full Text] [Related]
32. The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review. Lima WG; Brito JCM; Overhage J; Nizer WSDC Arch Virol; 2020 Aug; 165(8):1729-1737. PubMed ID: 32514689 [TBL] [Abstract][Full Text] [Related]
33. Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates. Rodrigues L; Bento Cunha R; Vassilevskaia T; Viveiros M; Cunha C Molecules; 2022 Apr; 27(9):. PubMed ID: 35566073 [TBL] [Abstract][Full Text] [Related]
35. Repositioning of histamine H Ge S; Wang X; Hou Y; Lv Y; Wang C; He H Eur J Pharmacol; 2021 Apr; 896():173897. PubMed ID: 33497607 [TBL] [Abstract][Full Text] [Related]
36. Mapping the SARS-CoV-2-Host Protein-Protein Interactome by Affinity Purification Mass Spectrometry and Proximity-Dependent Biotin Labeling: A Rational and Straightforward Route to Discover Host-Directed Anti-SARS-CoV-2 Therapeutics. Terracciano R; Preianò M; Fregola A; Pelaia C; Montalcini T; Savino R Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33430309 [TBL] [Abstract][Full Text] [Related]
37. Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study. Shahbazi B; Mafakher L; Teimoori-Toolabi L J Mol Model; 2022 Mar; 28(4):82. PubMed ID: 35249180 [TBL] [Abstract][Full Text] [Related]
38. A computational approach to aid clinicians in selecting anti-viral drugs for COVID-19 trials. Mongia A; Saha SK; Chouzenoux E; Majumdar A Sci Rep; 2021 Apr; 11(1):9047. PubMed ID: 33907209 [TBL] [Abstract][Full Text] [Related]
39. Human endeavor for anti-SARS-CoV-2 pharmacotherapy: A major strategy to fight the pandemic. Wang R; Stephen P; Tao Y; Zhang W; Lin SX Biomed Pharmacother; 2021 May; 137():111232. PubMed ID: 33486202 [TBL] [Abstract][Full Text] [Related]
40. Combined deep learning and molecular docking simulations approach identifies potentially effective FDA approved drugs for repurposing against SARS-CoV-2. Anwaar MU; Adnan F; Abro A; Khan RA; Rehman AU; Osama M; Rainville C; Kumar S; Sterner DE; Javed S; Jamal SB; Baig A; Shabbir MR; Ahsan W; Butt TR; Assir MZ Comput Biol Med; 2022 Feb; 141():105049. PubMed ID: 34823857 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]